...
机译:分子信息的可行性和益处,对复发或难治性弥漫性大B细胞淋巴瘤患者的早期临床试验
Inst Gustave Roussy Villejuif France;
Gustave Roussy Hematol Transfert Lab Villejuif France;
Gustave Roussy Drug Dev Dept Villejuif France;
Gustave Roussy Canc Campus Dept Hematol Villejuif France;
Inst Gustave Roussy Dept Hematol Villejuif France;
Gustave Roussy Canc Campus Dept Hematol Villejuif France;
Gustave Roussy Villejuif France;
Gustave Roussy Canc Ctr Dept Hematol Villejuif France;
Gustave Roussy Villejuif France;
Gustave Roussy Villejuif France;
Gustave Roussy Villejuif France;
Gustave Roussy Villejuif France;
Gustave Roussy Canc Campus Villejuif France;
Gustave Roussy Canc Campus Villejuif France;
Gustave Roussy Villejuif France;
Gustave Roussy Villejuif France;
Gustave Roussy Villejuif France;
Gustave Roussy Villejuif France;
Gustave Roussy Villejuif France;
Gustave Roussy Villejuif France;
Gustave Roussy Canc Campus Villejuif France;
Univ Paris Saclay Gustave Roussy DITEP Villejuif France;
机译:分子信息的可行性和益处,对复发或难治性弥漫性大B细胞淋巴瘤患者的早期临床试验
机译:I / II期试验评估挽救疗法的安全性,可行性和活性,该疗法由mTOR抑制剂Temsirolimus联合利妥昔单抗和DHAP的标准疗法组成,用于治疗复发性或难治性弥漫性大细胞B细胞淋巴瘤患者-STORM试用
机译:患有复发或难治性弥漫性大B细胞淋巴瘤的患者的结果包括在I期临床试验中
机译:患者弥漫性大B细胞淋巴瘤细胞株和血清中microRNA-21的表达及临床意义
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:I / II期试验评估挽救疗法的安全性可行性和活性该疗法由mTOR抑制剂Temsirolimus联合利妥昔单抗和DHAP的标准疗法组成用于治疗复发性或难治性弥漫性大细胞B细胞淋巴瘤患者– STORM试用
机译:I / II期试验评估挽救疗法的安全性,可行性和活性,该疗法由mTOR抑制剂Temsirolimus联合利妥昔单抗和DHAP的标准疗法组成,用于治疗复发性或难治性弥漫性大细胞B细胞淋巴瘤患者– STORM试用